Merus N.V. (NASDAQ:MRUS) has been assigned an average rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $31.33.

MRUS has been the topic of several recent research reports. ValuEngine raised shares of Merus N.V. from a “sell” rating to a “hold” rating in a research report on Saturday, May 20th. Wedbush reaffirmed an “outperform” rating and issued a $32.00 price target on shares of Merus N.V. in a research report on Tuesday, June 6th. Zacks Investment Research cut shares of Merus N.V. from a “hold” rating to a “sell” rating in a research report on Wednesday, June 28th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $31.00 price target on shares of Merus N.V. in a research report on Friday, July 14th. Finally, Royal Bank Of Canada initiated coverage on shares of Merus N.V. in a research report on Thursday. They issued an “outperform” rating on the stock.

Large investors have recently bought and sold shares of the business. Spark Investment Management LLC purchased a new stake in Merus N.V. in the 1st quarter valued at about $458,000. Renaissance Technologies LLC purchased a new stake in Merus N.V. in the 1st quarter valued at about $549,000. Victory Capital Management Inc. purchased a new stake in Merus N.V. in the 1st quarter valued at about $976,000. Iguana Healthcare Management LLC increased its stake in Merus N.V. by 16.7% in the 1st quarter. Iguana Healthcare Management LLC now owns 175,000 shares of the biotechnology company’s stock valued at $4,268,000 after buying an additional 25,000 shares during the last quarter. Finally, Nationwide Fund Advisors increased its stake in Merus N.V. by 13,206.9% in the 1st quarter. Nationwide Fund Advisors now owns 222,225 shares of the biotechnology company’s stock valued at $5,418,000 after buying an additional 220,555 shares during the last quarter. Hedge funds and other institutional investors own 32.16% of the company’s stock.

WARNING: This report was posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/09/14/merus-n-v-mrus-receives-consensus-recommendation-of-buy-from-analysts.html.

Merus N.V. (NASDAQ:MRUS) traded up 0.06% on Thursday, reaching $15.50. The company’s stock had a trading volume of 5,939 shares. The company’s market cap is $300.56 million. Merus N.V. has a 12 month low of $9.77 and a 12 month high of $29.75. The stock’s 50 day moving average price is $15.95 and its 200 day moving average price is $23.65.

Merus N.V. Company Profile

Receive News & Ratings for Merus N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus N.V. and related companies with MarketBeat.com's FREE daily email newsletter.